AUS
NZ
UK
CA
USA
IND
Highlights
- $1.41M R&D tax refund extends financial runway
- US FDA review of Adult App progressing steadily
- Infant App launches with strong early reception
PainChek (ASX:PCK) is making notable strides in its mission to transform pain assessment through technology. The company has received a research and development (R&D) tax refund of $1.41 million for the 2024 financial year. This funding will support upcoming milestones as the company expands both its product offerings and global reach.
Advancing Toward US Market Entry
A key development is the continued progress of the US Food and Drug Administration (FDA) review of PainChek’s Adult App. A meeting with the FDA has been scheduled for April 2025, with regulatory clearance anticipated in the first half of the same year. If approved, this would open the doors to the US aged care sector—a market estimated to be worth approximately USD $100 million annually for this kind of digital solution.
The Adult App is designed to assist caregivers in identifying and monitoring pain in individuals who may not be able to verbalize their discomfort, such as those living with dementia. Entry into the US healthcare system could significantly elevate PainChek's presence and adoption globally, positioning the technology as a leading digital pain assessment tool.
New Offering for Infant Care
In parallel with regulatory progress, PainChek has also expanded its product suite with the launch of its PainChek® Infant App on the Apple App Store in Australia. The app is priced at $99.99 per year and targets parents seeking reliable tools to assess pain in infants who cannot express their feelings.
Initial feedback from early users has been positive, supporting the app’s potential in home care settings. A wider marketing campaign is planned for the second quarter of 2025, signaling a strategic push to grow user adoption across broader demographics.
Strengthened Financial Position
The R&D tax refund not only demonstrates the company's commitment to innovation but also extends its financial capability to pursue key milestones. This includes advancing regulatory approvals and scaling new product launches, both domestically and internationally.
With a growing portfolio and clear roadmap ahead, PainChek (PCK) continues to build momentum in the digital health space, driving innovation in pain assessment technology across multiple age groups and care environments.
